These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 11120973)

  • 1. In vitro activity of trovafloxacin against Bacteroides fragilis in mixed culture with either Escherichia coli or a vancomycin- resistant strain of Enterococcus faecium determined by an anaerobic time-kill technique.
    Stearne LE; Kooi C; Goessens WH; Bakker-Woudenberg IA; Gyssens IC
    Antimicrob Agents Chemother; 2001 Jan; 45(1):243-51. PubMed ID: 11120973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo efficacy of trovafloxacin against Bacteroides fragilis in mixed infection with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model.
    Stearne LE; Gyssens IC; Goessens WH; Mouton JW; Oyen WJ; van der Meer JW; Verbrugh HA
    Antimicrob Agents Chemother; 2001 May; 45(5):1394-401. PubMed ID: 11302801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model.
    Hermsen ED; Hovde LB; Sprandel KA; Rodvold KA; Rotschafer JC
    Antimicrob Agents Chemother; 2005 Feb; 49(2):685-9. PubMed ID: 15673752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection of Enterococcus faecalis in mixed cultures with carbapenemase-producing Escherichia coli and Bacteroide fragilis: effect of the bacterial load.
    Sevillano D; Aguilar L; Alou L; Giménez MJ; Cafini F; González N; Prieto J
    Rev Esp Quimioter; 2013 Sep; 26(3):220-5. PubMed ID: 24080888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of trovafloxacin (with or without ampicillin-sulbactam) against enterococci in an in vitro dynamic model of infection.
    Zinner SH; Gilbert D; Dudley MN
    Antimicrob Agents Chemother; 1998 Jan; 42(1):72-7. PubMed ID: 9449263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of recombinant murine granulocyte colony-stimulating factor with or without fluoroquinolone therapy on mixed-infection abscesses in mice.
    Stearne LE; Vonk AG; Kullberg BJ; Gyssens IC
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3668-75. PubMed ID: 16127038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of trovafloxacin in an in vitro pharmacodynamic simulation of an intraabdominal infection.
    Alou L; Anta ML; Del Potro MG; Fuentes F; Balcabao IP; Gomez-Lus ML; Prieto J
    Int J Antimicrob Agents; 1999 Jul; 12(2):135-9. PubMed ID: 10418758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives.
    Cafini F; Aguilar L; González N; Giménez MJ; Torrico M; Alou L; Sevillano D; Vallejo P; Prieto J
    J Antimicrob Chemother; 2007 Jun; 59(6):1185-9. PubMed ID: 17412725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics and microbiology of trovafloxacin in animal models of surgical infection.
    Onderdonk AB
    Am J Surg; 1998 Dec; 176(6A Suppl):39S-45S. PubMed ID: 9935256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Activity of trovafloxacin and ten other antimicrobials against gram negative anaerobic bacilli].
    Chávez M; García López JL; Coronilla J; Bernal S; Valverde A; Martín Mazuelos E
    Rev Esp Quimioter; 1998 Dec; 11(4):349-52. PubMed ID: 9990149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracellular activity of trovafloxacin (CP-99,219) against Enterococcus faecium.
    Herrera-Insúa I; Jacques-Palaz K; Murray BE; Rakita RM
    J Antimicrob Chemother; 1997 Apr; 39(4):552-3. PubMed ID: 9145833
    [No Abstract]   [Full Text] [Related]  

  • 12. Exposure-response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria.
    Sevillano D; Aguilar L; Alou L; Giménez MJ; González N; Torrico M; Cafini F; Garcia-Rey C; Garcia-Escribano N; Prieto J
    Int J Antimicrob Agents; 2010 Aug; 36(2):137-44. PubMed ID: 20462741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changing patterns of fluoroquinolone resistance among Bacteroides fragilis group organisms over a 6-year period (1997-2002).
    Betriu C; Rodríguez-Avial I; Gómez M; Culebras E; Picazo JJ
    Diagn Microbiol Infect Dis; 2005 Nov; 53(3):221-3. PubMed ID: 16243476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis.
    Girard AE; Girard D; Gootz TD; Faiella JA; Cimochowski CR
    Antimicrob Agents Chemother; 1995 Oct; 39(10):2210-6. PubMed ID: 8619569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of piperacillin/tazobactam and ertapenem against Bacteroides fragilis and Escherichia coli in pure and mixed cultures.
    Valéria Dos Santos K; Diniz CG; Coutinho SC; Apolônio ACM; Geralda de Sousa-Gaia L; Nicoli JR; Farias LM; Roque de Carvalho MA
    J Med Microbiol; 2007 Jun; 56(Pt 6):798-802. PubMed ID: 17510265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluoroquinolone resistance in Bacteroides fragilis following sparfloxacin exposure.
    Peterson ML; Hovde LB; Wright DH; Hoang AD; Raddatz JK; Boysen PJ; Rotschafer JC
    Antimicrob Agents Chemother; 1999 Sep; 43(9):2251-5. PubMed ID: 10471574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The in-vitro activity of trovafloxacin, a new fluoroquinolone, against Gram-positive bacteria.
    Sefton AM; Maskell JP; Rafay AM; Whiley A; Williams JD
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():57-62. PubMed ID: 9222071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY333328), against Staphylococcus aureus and Enterococcus faecium.
    Mercier RC; Stumpo C; Rybak MJ
    J Antimicrob Chemother; 2002 Jul; 50(1):19-24. PubMed ID: 12096002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of moxifloxacin against Bacteroides fragilis and Escherichia coli in an in vitro pharmacokinetic/pharmacodynamic model employing pure and mixed cultures.
    Schaumann R; Goldstein EJ; Forberg J; Rodloff AC
    J Med Microbiol; 2005 Aug; 54(Pt 8):749-753. PubMed ID: 16014428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo efficacy of trovafloxacin (CP-99,217), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli.
    Thadepalli H; Reddy U; Chuah SK; Thadepalli F; Malilay C; Polzer RJ; Hanna N; Esfandiari A; Brown P; Gollapudi S
    Antimicrob Agents Chemother; 1997 Mar; 41(3):583-6. PubMed ID: 9055997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.